# ACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidates

- Link: https://www.thailand-business-news.com/pr-news/acrobiosystems-collaborates-with-carterra-accelerating-large-scale-characterization-of-potential-drug-candidates
- Published: 2026-04-30T07:00:00+07:00
- Author: PR Newswire

TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ — ACROBiosystems, a company 
dedicated to being a cornerstone of the global biopharmaceutical and healthcare 
industries, announces its collaboration with Carterra, a company focused on innovative
technologies designed to accelerate the discovery of novel therapeutic antibodies.
Through the synergy of ACROBiosystems’ "FLAG" multi-pass transmembrane proteins 
and Carterra’s LSA platform, large-scale comprehensive characterization of drug 
candidates can be rapidly performed using high-throughput surface plasmon resonance(
HT-SPR).

Transmembrane proteins, especially multi-pass ones, have been considered as highly
research‑worthy yet ‘undruggable’ targets. Many practical limitations remain due
to the challenges of working with proteins that are not highly stable in the absence
of a native cell-membrane environment.

To overcome this challenge, ACROBiosystems has established its "FLAG" technology
platform. This integrated platform employs multiple innovative approaches to develop
a full range of high-quality, full-length targets. These proteins exhibit stabilized
structures and high biological activity, and the portfolio includes key targets 
such as CD20, Claudin18.2/18.1/6/9, GPRC5D, CCR8, STEAP1/2/3/4, GLP-1R, and GIPR.
They are designed to facilitate and accelerate mechanistic research and drug discovery.

The combination of these stable transmembrane proteins with Carterra’s high-throughput
platform creates a robust solution for candidate screening. The use of high-quality,
full-length transmembrane proteins is critical for the accurate characterization
of drug candidates. Following transmembrane protein evaluations to confirm purity,
structure and bioactivity, HT-SPR can subsequently be performed with confidence 
to screen for drug candidates. These techniques highlight that with stable receptor
formats, both generalized binding and detailed kinetics can be ascertained. The 
rapid throughput of the Carterra LSA platform reduces the receptor’s required stability
time and mitigates activity losses that can occur in slower, lower-throughput screening
assays. While this work was done using intact monoclonal antibodies, the approach
could easily be extended to any drug format including nanobodies, scFvs, aptamers,
and even arrays of DEL compounds.

Together, ACROBiosystems’ expertise in developing high-quality recombinant proteins
and Carterra’s innovative LSA platform enables researchers to access broader and
deeper information on thousands of potential drug candidates. And which shall bring
a significant acceleration of the research and development process for groundbreaking
therapies.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [ACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidates ](http://www.prnasia.com/story/archive/4946721_AE46721_0?rand=184833)